hC Bioscience Announces Program in Duchenne Muscular Dystrophy and Reports In Vivo Data From tRNA-based Protein Editing Platform
hC Bioscience Presents Preclinical Data at ASGCT Showing Strong Potential in Hemophilia A Using tRNA-based Protein Editing Platform
hC Bioscience Announces Lead Program in Hemophilia and Reports Positive Preclinical Data on Novel Protein Editing Approach Using Anticodon Engineered tRNA
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc., a biotech company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases and cancer, today announced it has expanded its executive and research & development teams with the additions of Yosef Landesman, Ph.D., as chief scientific officer and Gautam Goel, Ph.D., as chief data science officer.